Status on Trajenta’s patent suits, will it lead to ‘composition’ too?
The Boehringer Ingelheim’s antidiabetic which recorded KRW 26.1 billion outpatient prescriptions only in the first half of the year, ‘Trajenta’ has become a target of many pharmaceutical companies to nullify its patents.
According to the Intellectual Property Tribunal’s lawsuit status, complains...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
